

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
1 April 2004 (01.04.2004)

PCT

(10) International Publication Number
WO 2004/026911 A1

(51) International Patent Classification⁷: **C07K 16/46**,
A61K 47/48, 39/395

(21) International Application Number:
PCT/EE2003/000005

(22) International Filing Date:
16 September 2003 (16.09.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
P200200531 17 September 2002 (17.09.2002) EE

(71) Applicant (for all designated States except US): INBIO
OÜ [EE/EE]; Sakala 17, 10141 Tallinn (EE).

(72) Inventors; and

(75) Inventors/Applicants (for US only): VALKNA, Andres
[EE/EE]; Sakala 17, 10141 Tallinn (EE). KOGERMAN,
Priit [EE/EE]; Sakala 17, 10141 Tallinn (EE).

(74) Agent: SARAP, Margus; Käosaar & Co Patent Agency,
Tähe 94, 50107 Tartu (EE).

(81) Designated States (national): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE,
GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR,
KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK,
MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT,
RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR,
TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,
ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO,
SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM,
GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report
- before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments

For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.

(54) Title: OBTAINING AND USE OF THERAPEUTIC ANTIBODIES ENTERING INTO THE CELL

(57) Abstract: The invention relates to the development of a novel technology of (cancer-)specific antibodies entering into the cell and their use for treatment of human diseases (primarily cancer). Such antibody (drug) would act by directly modulating the cancer-generating signals. The expected effects and principles of action of such antibodies are inactivation of intracellular proteins and thus they could be used for the treatment of diseases, where the activity of intracellular proteins must be modulated for effective treatment (primarily malignant tumors, but also many other diseases, which can be treated by inactivation of intracellular proteins). Above-mentioned antibody technology would also be applied elsewhere (e.g. scientific laboratories, that are engaged in investigation of intracellular proteins etc).

BEST AVAILABLE COPY

WO 2004/026911 A1